Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE versus POLOCAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE versus POLOCAINE MPF.
ALPHACAINE vs POLOCAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Polocaine-MPF (mepivacaine hydrochloride) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby preventing the initiation and propagation of nerve impulses. This results in reversible loss of sensation in the area of administration.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Adults: 1-2 cartridges (1.8 mL each) of 2% lidocaine with 1:100,000 epinephrine administered via local infiltration or nerve block, not to exceed 7 mg/kg (maximum 500 mg) for lidocaine.
None Documented
None Documented
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal elimination half-life: 1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 4-6 hours) and severe renal impairment. Clinical context: short half-life supports continuous infusion for sustained effect.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Renal: >90% as metabolites, primarily 4-hydroxy-2',6'-dimethylacetanilide and pipecoloxylidide; unchanged drug <5%. Biliary/fecal: <5%.
Category C
Category C
Local Anesthetic
Local Anesthetic